362-07-2
362-07-2
Chemical Structure
2-Methoxyestradiol
Synonym(s): 2-ME2; NSC-659853
- CAS No.: 362-07-2
- Formula:C19H26O3
- Molecular Weight:302.41
IUPAC Name: (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
InChIKey: CQOQDQWUFQDJMK-SSTWWWIQSA-N
SMILES: OC1=CC2=C([C@]3(CC[C@@]4([C@H](CC[C@]4([C@@]3(CC2)[H])[H])O)C)[H])C=C1OC
Biological Activity: 2-Methoxyestradiol (2-ME2; NSC-659853) is an endogenous steroid metabolite generated from 17β-estradiol, possessing various activities such as antitumor and antiangiogenic effects. 2-Methoxyestradiol competitively binds to the colchicine-binding site of tubulin (tubulin), interfering with microtubule assembly dynamics. 2-Methoxyestradiol inhibits CYP1A1/CYP1B1, HIF-1α/2α, and superoxide dismutase, activates the JNK signaling pathway, elevates ROS levels, and induces cell cycle arrest and apoptosis (apoptosis). 2-Methoxyestradiol is used in cancer-related research, such as breast cancer, prostate cancer, and multiple myeloma[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
2-Methoxyestradiol | 99.76% | 2-Methoxyestradiol (2-ME2; NSC-659853) is an endogenous steroid metabolite generated from 17β-estradiol, possessing various activities such as antitumor and antiangiogenic effects. 2-Methoxyestradiol competitively binds to the colchicine-binding site of tubulin (tubulin), interfering with microtubule assembly dynamics. 2-Methoxyestradiol inhibits CYP1A1/CYP1B1, HIF-1α/2α, and superoxide dismutase, activates the JNK signaling pathway, elevates ROS levels, and induces cell cycle arrest and apoptosis (apoptosis). 2-Methoxyestradiol is used in cancer-related research, such as breast cancer, prostate cancer, and multiple myeloma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
2-Methoxyestradiol (Standard) | ≥98% | 2-Methoxyestradiol (Standard) (2-ME2 (Standard); NSC-659853 (Standard)) is the analytical standard of 2-Methoxyestradiol (HY-12033). This product is intended for research and analytical applications. 2-Methoxyestradiol (2-ME2; NSC-659853) is an endogenous steroid metabolite generated from 17β-estradiol, possessing various activities such as antitumor and antiangiogenic effects. 2-Methoxyestradiol competitively binds to the colchicine-binding site of tubulin (tubulin), interfering with microtubule assembly dynamics. 2-Methoxyestradiol inhibits CYP1A1/CYP1B1, HIF-1α/2α, and superoxide dismutase, activates the JNK signaling pathway, elevates ROS levels, and induces cell cycle arrest and apoptosis (apoptosis). 2-Methoxyestradiol is used in cancer-related research, such as breast cancer, prostate cancer, and multiple myeloma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
2-Methoxyestradiol-d5 | 98.67% | 2-Methoxyestradiol-d5 (2-ME2-d5; NSC-659853-d5) is the deuterated-labeled 2-Methoxyestradiol (HY-12033). 2-Methoxyestradiol (2-ME2; NSC-659853) is an endogenous steroid metabolite generated from 17β-estradiol, possessing various activities such as antitumor and antiangiogenic effects. 2-Methoxyestradiol competitively binds to the colchicine-binding site of tubulin (tubulin), interfering with microtubule assembly dynamics. 2-Methoxyestradiol inhibits CYP1A1/CYP1B1, HIF-1α/2α, and superoxide dismutase, activates the JNK signaling pathway, elevates ROS levels, and induces cell cycle arrest and apoptosis (apoptosis). 2-Methoxyestradiol is used in cancer-related research, such as breast cancer, prostate cancer, and multiple myeloma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
2-Methoxyestradiol-13C,d3 | 2-Methoxyestradiol-13C,d3 (2-ME2-13C,d3; NSC-659853-13C,d3) is the deuterated, 13C-labeled 2-Methoxyestradiol (HY-12033). 2-Methoxyestradiol (2-ME2; NSC-659853) is an endogenous steroid metabolite generated from 17β-estradiol, possessing various activities such as antitumor and antiangiogenic effects. 2-Methoxyestradiol competitively binds to the colchicine-binding site of tubulin (tubulin), interfering with microtubule assembly dynamics. 2-Methoxyestradiol inhibits CYP1A1/CYP1B1, HIF-1α/2α, and superoxide dismutase, activates the JNK signaling pathway, elevates ROS levels, and induces cell cycle arrest and apoptosis (apoptosis). 2-Methoxyestradiol is used in cancer-related research, such as breast cancer, prostate cancer, and multiple myeloma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
2-Methoxyestradiol-13C6 | 2-Methoxyestradiol-13C6 (2-ME2-13C6; NSC-659853-13C6) is the 13C-labeled 2-Methoxyestradiol (HY-12033). 2-Methoxyestradiol (2-ME2; NSC-659853) is an endogenous steroid metabolite generated from 17β-estradiol, possessing various activities such as antitumor and antiangiogenic effects. 2-Methoxyestradiol competitively binds to the colchicine-binding site of tubulin (tubulin), interfering with microtubule assembly dynamics. 2-Methoxyestradiol inhibits CYP1A1/CYP1B1, HIF-1α/2α, and superoxide dismutase, activates the JNK signaling pathway, elevates ROS levels, and induces cell cycle arrest and apoptosis (apoptosis). 2-Methoxyestradiol is used in cancer-related research, such as breast cancer, prostate cancer, and multiple myeloma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lakhani NJ, et al. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy. 2003 Feb;23(2):165-72.
- [2]. Mooberry SL, et al. Mechanism of action of 2-methoxyestradiol: new developments. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2003 Dec;6(6):355-61. [Content Brief]
- [3]. LaVallee TM, et al. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer research. 2002 Jul 01;62(13):3691-7. [Content Brief]
- [4]. Pribluda VS, et al. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer metastasis reviews. 2000;19(1-2):173-9.
